Is Eaton Vance Municipal Income 2028 Term Trust (ETX) a Buy, Sell, or Hold?
NYSE : ETX
Eaton Vance Municipal Income 2028 Term Trust — News
$18.57 USD
-$0.05 (-0.27%)
- Volume
- 108
- Average Volume
- 13.58K
- Market Capitalization
- $202.18M
- P/E Ratio
- 24.12
- Dividend Yield
- 5.05%
- Price Target
- Year High
- $20.00
- Year Low
- $18.07
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.21
| Source | Headline |
|---|---|
|
Encoded Therapeutics Presents New Clinical Data from POLARIS Phase 1/2 Trials of ETX101 Gene Therapy in Dravet Syndrome at the ASGCT 2026 Presidential Symposium
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ASGCT2026--Encoded Therapeutics, Inc. (“Encoded”), a clinical‑stage biotechnology company developing precision genetic medicines for severe neurological disorders, today will present an expanded dataset from the ongoing POLARIS Phase 1/2 trials of ETX101, its investigational AAV9‑based gene regulation therapy designed as a one‑time, disease‑modifying treatment for SCN1A+ Dravet syndrome. The update includes additional patients, early data from the top dose lev. businesswire.com - 2026-05-13 06:00:00 |
